Christian Stone, MD
Gastroenterology · Las Vegas, NVNPI 1750308284
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $954,107 of the $1,135,367 with a category attached, or 84.0%. 41 manufacturers reported payments, led by AbbVie at 34.9% of the total. Among gastroenterology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,569 payments — averaging $723.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$396K
- E.r. Squibb & Sons, L.L.C.$189K
- Takeda Pharmaceuticals U.S.A., Inc.$144K
- Janssen Scientific Affairs, LLC$124K
- Pfizer$79K
- Lilly USA, LLC$77K
- plus $126K from 35 others
Across 542 payments — averaging $4783.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.2M
- Eli Lilly$279K
- Sanofi$249K
- Takeda Pharmaceuticals U.S.A., Inc.$223K
- Janssen Research & Development, LLC$199K
- Teva Pharmaceuticals USA, Inc.$133K
- plus $274K from 4 others
What the payments were for
- Consulting fees$42,9024%
- Speaking & faculty fees$954,10784%
- Travel & lodging$98,7839%
- Food & beverage$39,3863%
- Education$1900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPOSIA$200,732
- STELARA$176,024
- Skyrizi$147,325
- Rinvoq$132,959
- Entyvio$92,360
- Humira$64,140
- OMVOH$61,627
- Tremfya$51,992
- GATTEX$50,132
- XELJANZ$41,137
- VELSIPITY$32,592
- INTERSTIM$23,735
- DIFICID$3,603
- ZINPLAVA$3,603
- ZYMFENTRA$3,317
- Talicia$2,634
- Sucraid$1,000
- DUPIXENT$421
- ESD - Core Endoscopy$149
- LINX Reflux Management System$125
How this compares
$1,135,367 in reported general payments places this provider in the 95th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 47 | $451,349 |
| RinvoqUpadacitinib | 40 | $300,414 |
| LinzessLinaclotide | 31 | $17,417 |
| TrulancePlecanatide | 11 | $13,652 |
| Mesalamine | 27 | $9,938 |
| Budesonide DrBudesonide | 30 | $3,116 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 193 | $2,994 |
| Azathioprine | 43 | $2,543 |
| Budesonide EcBudesonide | 12 | $2,301 |
| CholestyramineCholestyramine (With Sugar) | 13 | $1,844 |
| Lubiprostone | 18 | $1,804 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 11 | $1,787 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 21 | $1,452 |
| Nortriptyline Hcl | 200 | $1,441 |
| Omeprazole | 92 | $958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $395,801 | $317,83171 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $564 | $13,65211 claims |
| Braintree Laboratories, Inc.Sutab | $145 | $1,78711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in Las Vegas
- James HanLas Vegas$47K
- Filippo CremoniniLas Vegas$36K
- Vijay JayaramanLas Vegas$28K
- Gary ChenLas Vegas$27K
- David ShihLas Vegas$26K
- Noel FajardoLas Vegas$22K
- Frank FarisLas Vegas$14K
- Tarek AmmarLas Vegas$14K
- Eladio CarreraLas Vegas$13K
- Uday SaraiyaLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.